Codiak BioSciences, Inc. financial metrics

Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q3 2022.

Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
03 Nov 2022

Quick Takeaways

  • Codiak BioSciences, Inc. financial facts are built from SEC company filings data.
  • Latest metrics period on this page: Q3 2022.
  • Headline metric: Return On Equity -48%.

What Changed

  • Return On Equity YoY change: <span class="text-red-600">-178%</span>.
  • Most recent SEC facts end date: 27 Oct 2022.

Why This Matters

  • This gives a beginner-friendly first read before you inspect detailed formulas and metric tables.
  • Every metric card links to a deeper SEC-backed history page for verification.

Official SEC Source

Based on latest 10-Q/10-K

Facts and ratios are grounded in SEC company facts linked to the latest 10-Q/10-K cycle.

See Original Filing

Latest SEC snapshot (2022-10-27) highlights Return On Equity -47.8%, Return On Assets -11.9%, and Operating Margin -156.5%.

Financial Quality Score

Transparent 0-100 scoring model based on profitability, financial health, and growth factors.

35.6/100

Weak Confidence medium

Return On Equity

-48%

Metric score 0.0/100

Return On Assets

-12%

Metric score 0.0/100

Financial Health

Current Ratio
4.24x
Debt to Equity
2.18x

Strengths

Revenues YoY and NetIncomeLoss YoY

Watchpoints

Return On Equity, Return On Assets, and Operating Margin

Key metrics snapshot

Return On Equity

-48%

YoY: -178%

Industry median: -47% (n=218)

View history

Return On Assets

-12%

YoY: -78%

Industry median: -44% (n=217)

View history

Operating Margin

-156%

YoY: -63%

Industry median: -263% (n=94)

View history

Current Ratio

4.24x

YoY: -5.8%

Industry median: 3.67x (n=218)

View history

Debt-to-equity

2.18x

YoY: -27%

Industry median: 0.31x (n=169)

View history

Revenues YoY

102%

YoY:

Industry median: 11% (n=96)

View history

NetIncomeLoss YoY

76%

YoY:

Industry median: -12% (n=211)

View history

Profitability

Metric Latest value YoY change
Return On Equity -48% -178%
Return On Assets -12% -78%
Operating Margin -156% -63%

Financial Health

Metric Latest value YoY change
Current Ratio 4.24x -5.8%
Debt-to-equity 2.18x -27%

Growth

Metric Latest value YoY change
Revenues YoY 102%
NetIncomeLoss YoY 76%

Share Metrics

Metric Latest value YoY change
Entity Common Stock, Shares Outstanding 36,829,626 +65%
Common Stock, Shares, Outstanding 36,829,626 +65%
Common Stock, Value, Issued $4,000 +100%
Weighted Average Number of Shares Outstanding, Basic 25,159,757 +13%
Weighted Average Number of Shares Outstanding, Diluted 25,159,757 +13%

Additional Metrics

Metric Latest value YoY change
Research and Development Expense $55,312,000 -9%
General and Administrative Expense $27,552,000 +3.5%
Operating Income (Loss) $53,304,000 +24%
Nonoperating Income (Expense) $35,885,000
Earnings Per Share, Basic -0.77 +21%
Earnings Per Share, Diluted -0.77 +21%
Cash and Cash Equivalents, at Carrying Value $51,762,000 -47%
Cash, Cash Equivalents, and Short-term Investments $51,800,000 -47%
Assets, Current $61,233,000 -41%
Property, Plant and Equipment, Net $20,538,000 -30%
Operating Lease, Right-of-Use Asset $20,955,000 -1.4%
Assets $134,396,000 -15%
Accounts Payable, Current $1,956,000 -2.1%
Employee-related Liabilities, Current $4,266,000 -27%
Accrued Liabilities, Current $8,126,000 -13%
Liabilities, Current $14,456,000 -37%
Operating Lease, Liability, Noncurrent $32,573,000 -6%
Liabilities $95,467,000 -23%
Retained Earnings (Accumulated Deficit) $359,328,000 -5.1%
Stockholders' Equity Attributable to Parent $38,929,000 +14%
Liabilities and Equity $134,396,000 -15%
Common Stock, Shares Authorized 150,000,000 0%
Common Stock, Shares, Issued 36,829,626 +65%
Common Stock, Par or Stated Value Per Share 0 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $55,932,000 -46%
Operating Lease, Liability $35,584,000 -4.1%
Lessee, Operating Lease, Liability, to be Paid $50,253,000 -9.3%
Operating Lease, Liability, Current $3,011,000 +24%
Lessee, Operating Lease, Liability, to be Paid, Year Two $6,625,000 +5%
Lessee, Operating Lease, Liability, to be Paid, Year One $6,436,000 +5.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $14,669,000 -20%
Lessee, Operating Lease, Liability, to be Paid, Year Three $6,820,000 +5%
Lessee, Operating Lease, Liability, to be Paid, Year Four $7,020,000 +4.9%
Additional Paid in Capital $398,253,000 +5.9%
Share-based Payment Arrangement, Expense $9,926,000 -2.4%
Interest Expense $2,612,000 -6.7%

How we score

This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.

Metric Weight V1 threshold
ROIC205% to 20%
ROE158% to 25%
ROA102% to 10%
Operating Margin55% to 25%
Current Ratio121.0x to 2.0x
Quick Ratio80.8x to 1.5x
Debt to Equity100.3x to 2.0x (lower is better)
Revenue YoY10-10% to +20%
Net Income YoY10-10% to +20%

How Calculated (standard_v1)

Metrics are computed with a market-consensus convention designed for cross-portal comparability.

  • TTM Operating Income / TTM Revenues
  • Current Assets / Current Liabilities (latest instant quarter)
  • (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
  • Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
  • TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
  • TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
  • TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
  • TTM Revenues YoY
  • TTM Net Income YoY